Imatinib-structure (Imatinib Structure)
Imatinib Mesylate Tablet, Film Coated
Product Images NDC 47335-475
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 47335-475). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Spl Imatinib 100 mg
Each tablet contains Imatinib Mesylate equivalent to 100 mg of Matind base. The usual dosage is six packages per treatment. It should be stored at a temperature range of 15°C to 30°C (53°F to 85°F) with protection from moisture. Dispense it in a tight container as per the USP guidelines and keep it out of reach of children. This drug is imatinib mesylate and is manufactured and distributed by Novartis Pharmaceuticals. NDC number for this drug is 47335-472-81.*
Spl-imatinib-100 (Spl Imatinib 100)
This is a medication called Imatinib Mesylate that comes in tablet form with a strength equivalent to 100 mg of imatinib free base. The typical dosage is mentioned in the package insert. The tablets should be stored at controlled room temperature between 20-25°C (68°-77°F) and should be protected from moisture. It should be dispensed in a tight container, and kept out of reach of children. The description also includes some manufacturing information such as the NDC number, the manufacturer, the dosage form, and the number of tablets.*
Spl Imatinib 400 mg
Eschtablot Tablets contain 400mg of Imatinib Mesylate which is a medication used to treat certain types of cancer. The usual dosage is not readable. Store the tablets at a temperature of 20 to 25°C and protect them from moisture. The tablets come in a USP approved container. The medication should be kept out of the reach of children. The rest of the text is not readable.*
Spl-imatinib-400 (Spl Imatinib 400)
Each tablet of the medicine contains 400 mg of Imatinib Mesylate manufactured and distributed by Sun Pharmaceutical Industries, Inc. The recommended dosage can be found in the package insert. Store the tablets in a tightly closed container between a temperature range of 15°C to 30°C. The medicine should be protected from moisture and kept out of reach of children. The expiry date and Lot number is also mentioned.*
Spl Imatinib Fig 3
This is a graph representing the survival rate of patients taking Imatinib 400mg and those on placebo. The x-axis represents the survival time in months, while the y-axis represents the number of patients. Patients taking Imatinib 400mg had a higher survival rate compared to those on placebo. The italicized characters and numbers are not recognizable.*
Spl Imatinib Fig 4
Spl Imatinib Fig 5
This looks like the output of a survival analysis study. The hazard ratio for overall survival is 0.45, indicating a significant improvement in survival with treatment. There were two treatment groups: (1) manib and (2) Imatinib. The graph shows the survival time in months for each group. The X-axis shows the time in months, and the Y-axis shows the number of patients at risk. However, without more information on the study design, population, and variables, it is difficult to provide a complete description of the study.*
Spl-imatinib-fig1 (Spl Imatinib Fig1)
This is a statistical data table showing the number of patients with progression without progression for Imatinib Mesylate and 1FN+Ara-C arms. It also shows the number of patients censored at discontinuation and censored at last follow-up. The Hazard Ratio and Log-rank Test results are also provided. The description provides no further context or information for the table.*
Spl-imatinib-fig2 (Spl Imatinib Fig2)
This is a statistical table that presents information on the number of patients with Imatinib Mesylate and FN+Ara-C, who had progression to AP or BC during the study period. The table also presents the number of patients who were censored (had missing data) due to discontinuation or last follow-up for each of the treatment arms. The hazard ratio and confidence interval for progression to AP or BC between the two treatment arms are also shown, with a statistically significant result (p<0.001) based on a log-rank test. The table contains no non-English characters.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
